Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc.

Bullboard Posts

Comment by LaserStock29on Mar 20, 2020 1:39pm

201 Views

Post# 30831141

RE:RE:RE:RE:RE:Breakthrough status and IND application

fredgoodwinson wrote: Couldn`t agree more Enrique. Had long given up on the idea that the Trial was proceeding unhindered by now so for me today`s ann was a real positive - not just with the 2 extra treated but confirmation that all 12 to date will get the second treatment.That had been the real concern.

They were up to around 3 a month so even without more sites this hiatus should mean plenty of treatments in short order on resumption even without IND approval and will anyone not take the 12 month results for the first 12 seriously if they are good?

Silly price IMHO.

Yes.. lets keep the pps real low until a full 12 months have passed... the 3 month and 2nd treatment validating Dr Mandels 'toleration' quote.. is absolutely meaningless to staking a claim on the 1.1b market.

gimme a break....... we've gone from the company wanting to release P1 and P2 and regular updates.. to pretending to be a big pharma with quarterlies... and the negation of 3 months meaning anything which is barely tolerable to now what... suggesting that the validation of 2nd treatment safety will have no impact on the pps.

fred.. you should re-clarify your remarks.